Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
November 21, 2024 09:24 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that licenses innovations from Purdue Research Foundation, has developed a patent-pending antiviral...
[Latest] Global Dental Digital X-ray Market Size/Share Worth USD 6.7 Billion by 2033 at a 7.68% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 12, 2024 14:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dental Digital X-ray Market Size, Trends and Insights By Product (Digital X-ray...
[Latest] Global Cancer Cell Analysis Market Size/Share Worth USD 23.31 Billion by 2033 at a 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 06, 2024 13:00 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cell Analysis Market Size, Trends and Insights By Application (Cancer...
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
November 01, 2024 16:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
October 14, 2024 06:02 ET
|
GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
Global Sodium Channel Blockers Market to Reach US$ 9.96 Billion by 2030, Rising at a CAGR of 8.5% | Report by CoherentMI
March 07, 2024 08:11 ET
|
CMI
Burlingame, March 07, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Global Sodium Channel Blockers Market was valued at US$ 5.64 Billion in the year 2023 and is anticipated to...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...